• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed!

作者信息

Collette Laurence, Buyse Marc, Burzykowski Tomasz

出版信息

J Clin Oncol. 2007 Dec 10;25(35):5673-4; author reply 5674. doi: 10.1200/JCO.2007.14.5268.

DOI:10.1200/JCO.2007.14.5268
PMID:18065747
Abstract
摘要

相似文献

1
Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed!
J Clin Oncol. 2007 Dec 10;25(35):5673-4; author reply 5674. doi: 10.1200/JCO.2007.14.5268.
2
Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.多中心随机II期研究：多西他赛、雌莫司汀和泼尼松两种给药方案对比米托蒽醌加泼尼松用于转移性激素难治性前列腺癌患者的疗效
J Clin Oncol. 2005 May 20;23(15):3343-51. doi: 10.1200/JCO.2005.12.187. Epub 2005 Feb 28.
3
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.多西他赛与雌莫司汀对比米托蒽醌和泼尼松治疗晚期难治性前列腺癌的疗效
N Engl J Med. 2004 Oct 7;351(15):1513-20. doi: 10.1056/NEJMoa041318.
4
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.转移性激素难治性前列腺癌中的前列腺特异性抗原与疼痛替代分析
J Clin Oncol. 2007 Sep 1;25(25):3965-70. doi: 10.1200/JCO.2007.11.4769.
5
Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?多西他赛联合雌莫司汀能否延长转移性激素难治性前列腺癌男性患者的生存期？
Nat Clin Pract Oncol. 2005 Feb;2(2):70-1. doi: 10.1038/ncponc0076.
6
Future directions in the treatment of androgen-independent prostate cancer.雄激素非依赖性前列腺癌的治疗新方向。
Urology. 2005 Jun;65(6 Suppl):8-12. doi: 10.1016/j.urology.2005.04.020.
7
Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916.多西他赛（泰索帝）与雌莫司汀联合用药对比米托蒽醌与泼尼松治疗激素难治性前列腺癌：西南肿瘤协作组9916研究的科学依据与设计
Semin Oncol. 1999 Oct;26(5 Suppl 17):55-60.
8
Which drug combination for hormone-refractory prostate cancer?哪种药物组合适用于激素难治性前列腺癌？
Expert Opin Pharmacother. 2005 Apr;6(4):667-70. doi: 10.1517/14656566.6.4.667.
9
Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases.他莫昔芬联合米托蒽醌及泼尼松治疗激素难治性前列腺癌的II期试验：有症状转移患者的高主观和客观缓解率
J Urol. 2005 Nov;174(5):1808-13; discussion 1813. doi: 10.1097/01.ju.0000176799.63184.99.
10
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.米托蒽醌联合泼尼松或单用泼尼松治疗有症状的激素抵抗性前列腺癌的化疗：一项以姑息治疗为终点的加拿大随机试验
J Clin Oncol. 1996 Jun;14(6):1756-64. doi: 10.1200/JCO.1996.14.6.1756.

引用本文的文献

1
Radiation dose-response (a Bayesian model) in the radiotherapy of the localized prostatic adenocarcinoma: the reliability of PSA slope changes as a response surrogate endpoint.局限性前列腺腺癌放射治疗中的辐射剂量反应（贝叶斯模型）：前列腺特异性抗原（PSA）斜率变化作为反应替代终点的可靠性
PeerJ. 2019 Jul 1;7:e7172. doi: 10.7717/peerj.7172. eCollection 2019.
2
Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy.二线化疗治疗转移性去势抵抗性前列腺癌男性患者中，前列腺特异性抗原变化可作为总生存的替代指标。
J Clin Oncol. 2013 Nov 1;31(31):3944-50. doi: 10.1200/JCO.2013.50.3201. Epub 2013 Oct 7.